Tag:
Phase II
Latest Headlines
Latest Headlines
UPDATED: Merck snags Chimerix antiviral HIV program in $168.5M deal
Research Triangle Park, NC-based Chimerix has inked its first big partnership, reaping a $17.5 million upfront payment and a promise of up to $151 million more from Merck, which gains rights to a mid-stage antiviral--CMX157--which has prospects as a new addition to future HIV cocktails.
UPDATED: Onyx clears big hurdle in high-stakes gamble on early carfilzomib approval
Onyx's risky attempt to win an approval for the multiple myeloma drug carfilzomib on the basis of mid-stage data from a single-arm study cleared a major hurdle yesterday evening when an FDA advisory group gave its drug a unanimous thumbs up.
Pfizer targets PhIII with pioneering meningitis B vax
Pharma giant Pfizer is making progress in the Phase II trial of a vaccine for meningitis serogroup B, for which there are no such preventive treatments available. This week the New York-based drugmaker's trial got some ink from media near some of the study sites in the Midwest.
Trial vets at Flexion claim PhII success with lead osteoarthritis drug
This morning, Flexion announced that they hit the proof-of-concept stage as planned. Top-line results demonstrated that the intra-articularly delivered FX005 hit its primary endpoint on pain relief and function among osteoarthritis patients.
UPDATED: Teen meningitis B vax successful in Phase II
A team from Australia has shown positive immune responses in a Phase II trial of Pfizer's meningitis B vaccine in teenagers.
Aveo Pharma flunks Phase II lung cancer study
Aveo's share price slid a modest 30 cents, or 2.53%, to $11.77, as of 10:30 a.m. ET Wednesday.
Halo takes the virtual approach to developing a DMD treatment
Halo Therapeutics may be the most virtual biotech company on the threshold of a mid-stage study.
Targacept scuttles diabetes drug program in fresh setback
A beleaguered Targacept took one step forward and two steps back today, killing a development program for TC-6987.
Did Big Pharma scuttle an attempt to radically restructure the approval pathway?
Sen. Kay Hagan's proposal to set up an accelerated approval pathway for experimental medications hasn't been universally embraced by everyone in the biopharma industry.
Adverse events force Conatus to shelve PhII study of lead HCV therapy
Earlier this year San Diego-based Conatus Pharmaceuticals was able to round up a $32.5 million B round from a group of venture backers which included Roche Ventures, largely based on the promise of
